RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

RxSight, Inc.NASDAQ: RXST

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -57.7%

Operating margin was -57.7% in Q1 FY2026, down 29.5 pp from a year earlier. On a trailing-twelve-month basis it was -43.4%, down 20.1 pp year over year. Over 3 fiscal years it widened by 93.4 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 8 analysts of -3.8% for the fiscal year ending Dec 2026, up from -35.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-57.7%-22.9 pp QoQ
Last fiscal yearDec 2025
-35.8%-9.5 pp YoY
LTMMar 2026
-43.4%-20.1 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-29.5 pp-0.6 pp+29.0 pp
1 year-9.5 pp+32.0 pp+41.5 pp
3 years+93.4 pp+9.6 pp-83.8 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-35.8%
Year-over-year change
-9.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 operating margin of -43.4% is the 7th highest of the 8 companies compared; the peer median is -12.1%.
  • Its year-over-year change of -20.1 pp is the lowest of 8, against a peer median of +2.4 pp.
  • Over three fiscal years its change of +93.4 pp compares with a peer median of +14.1 pp.
RXST Competitors Peer median
Operating Margin for RXST and competitors
Company Period LTM level YoY 3-year change
TCMDTactile Systems Technology, Inc.LTM Mar 20269.4% +2.4 pp+14.1 pp
DCTHDelcath Systems, Inc.LTM Mar 2026-1.8% +1.0 pp+1245.8 pp
CERSCerus CorporationLTM Mar 2026-7.9% +1.6 pp+3.4 pp
KIDSOrthoPediatrics Corp.LTM Mar 2026-12.1% +5.0 pp+8.5 pp
NPCENeuroPace, Inc.LTM Mar 2026-16.8% +6.0 pp+73.3 pp
TMCITreace Medical Concepts, Inc.LTM Mar 2026-26.9% -2.1 pp-0.9 pp
RXSTRxSight, Inc.LTM Mar 2026-43.4% -20.1 pp+93.4 pp
BFLYButterfly Network, Inc.LTM Mar 2026-79.1% +2.9 pp+174.5 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding RXST) -12.1%+2.4 pp+14.1 pp

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.59M49.01M89.08M139.93M134.48M
Cost of Revenue18.08M27.68M35.31M40.98M31.47M
Gross Profit4.52M21.33M53.77M98.94M103.01M
Gross Margin20.0%43.5%60.4%70.7%76.6%
Research & Development24.5M25.98M29.05M34.37M38.55M
Selling, General & Admin32.81M58.67M74.8M101.43M112.65M
Operating Expenses57.3M84.65M103.85M135.8M151.2M
Depreciation & Amortization3.99M4.02M4.24M3.62M0
EBITDA(41.01M)(57.78M)(41.04M)(23.76M)(38.84M)
EBITDA Margin-181.5%-117.9%-46.1%-17.0%-28.9%
Operating Income(52.79M)(63.32M)(50.09M)(36.86M)(48.19M)
Operating Margin-233.6%-129.2%-56.2%-26.3%-35.8%
Interest Income54K1.52M6.57M9.47M2.51M
Interest Expense3.68M4.95M3.31M21K40K
Other Income / Expenses4.11M(3.43M)1.5M9.45M9.31M
Income Before Tax(48.68M)(66.75M)(48.59M)(27.41M)(38.88M)
Pre-Tax Margin-215.5%-136.2%-54.5%-19.6%-28.9%
Income Tax Expense8K9K20K50K66K
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Net Margin-215.5%-136.2%-54.6%-19.6%-29.0%
EPS (Basic)(1.78)(2.41)(1.41)(0.71)(0.95)
EPS (Diluted)(1.78)(2.41)(1.41)(0.71)(0.95)
Weighted Avg Shares27.37M27.66M34.46M38.87M41.18M
Weighted Avg Shares (Diluted)27.37M27.66M34.46M38.87M41.18M

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.